The Medical Innovation Agenda for the 119th Congress
AdvaMed®’s medtech priorities for the 119th Congress highlight opportunities to address the most important issues facing patients and the medical technology industry today.
Resource Library
Access our full library of guidance, white papers, and other resources developed by and for the medical technology industry.
Filter By:
The Global Democratization of Point-of-Care & At-Home Diagnostic Testing
One of healthcare’s most extensive and rapidly expanding market segments, Pointof-Care (POC) and at-home rapid diagnostic testing, has become an ever-increasing crucial topic in the medical world since COVID-19 was…
AdvaMed® Response to Senate HELP Committee Regarding Reauthorization of Pandemic All-Hazards Preparedness Act
On March 29, AdvaMed® responded to the Senate HELP Committee’s request for information on policy priorities for the reauthorization of the Pandemic All-Hazards Preparedness Act (PAHPA).
A Framework for Comprehensive Assessment of the Value of Diagnostic Tests
It is critical for diagnostic test developers to demonstrate the value of their tests to a variety of stakeholders. This framework serves as a resource for members to assess and…
VALID Accommodations for Academic Medical Centers and Other Lab Tests
The VALID Act is carefully tailored to ensure continued access to tests offered by academic medical centers and other laboratories.
Listen to AdvaMed®'s Podcast
Brought to you by AdvaMed®, Medtech POV with Scott Whitaker is a podcast that covers the intersection of medtech and policy from every perspective.
AdvaMed® COVID Testing Supply Registry – Weekly Report
This report outlines a key data-driven summary of the U.S. COVID testing supply.
AdvaMed® Submits Comments on Genetic Testing in Oncology LCD
AdvaMed® submitted a letter to Medicare Administrative Contractors, Novitas and First Coast Service Options, regarding proposed LCDs on Genetic Testing in Oncology.
AdvaMedDx® COVID Testing Supply Retrospective Report
This report examines cumulative data from the first two years of the COVID Test Registry to demonstrate the mobilization of the diagnostics industry over the course of the pandemic.
